Cargando…

Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis

BACKGROUND AND AIM: Immune checkpoint inhibitors (ICIs) have been widely used in hepatocellular carcinoma (HCC), while only a subset of patients experience clinical benefit. We aimed to investigate the effects of viral etiology on response to ICIs in HCC and depict the tumor immune microenvironment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Ziniu, Dong, Zhaoru, Chen, Zhiqiang, Hong, Jianguo, Yan, Lunjie, Li, Haichao, Yao, Shengyu, Yan, Yuchuan, Yang, Yafei, Yang, Chuncheng, Li, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511422/ https://www.ncbi.nlm.nih.gov/pubmed/34659220 http://dx.doi.org/10.3389/fimmu.2021.733530

Ejemplares similares

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
por: Chen, Yunfei, et al.
Publicado: (2021)

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
por: Liu, Zhuoyan, et al.
Publicado: (2021)

Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma
por: Gao, Biao, et al.
Publicado: (2023)

Bibliometric study of immunotherapy for hepatocellular carcinoma
por: Li, Zhiyi, et al.
Publicado: (2023)

HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma
por: Shen, Chen, et al.
Publicado: (2023)

Immunotherapy of hepatocellular carcinoma: recent progress and new strategy
por: Li, Jiarui, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
por: Dai, Weijing, et al.
Publicado: (2022)

Editorial: NK cells in viral immunology and immunotherapy
por: Mulik, Sachin, et al.
Publicado: (2023)

Lymphoma Immunotherapy: Current Status
por: Zappasodi, Roberta, et al.
Publicado: (2015)

Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma
por: Hong, Ting, et al.
Publicado: (2022)

Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective
por: Chen, Shuling, et al.
Publicado: (2022)

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
por: Giraud, Julie, et al.
Publicado: (2021)

Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma
por: Tian, Zelin, et al.
Publicado: (2022)

Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy
por: Wang, Yanan, et al.
Publicado: (2022)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Xing, Rui, et al.
Publicado: (2021)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target
por: Jiang, Qianwei, et al.
Publicado: (2023)

Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma
por: Shi, Yanlong, et al.
Publicado: (2022)

Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
por: Liang, Xiaowei, et al.
Publicado: (2023)

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
por: Mao, Lili, et al.
Publicado: (2021)

Bromo‐ and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma
por: Liu, Chen, et al.
Publicado: (2020)

Editorial: Peptide-based immunotherapy against emerging viral infections
por: Jiang, Shisong
Publicado: (2023)

Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies
por: Dong, Yan, et al.
Publicado: (2021)

Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma
por: Xin, Hongjie, et al.
Publicado: (2023)

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
por: Shen, Jianming, et al.
Publicado: (2022)

Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma
por: Zhao, Ming, et al.
Publicado: (2023)

Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma
por: Tang, Yuqin, et al.
Publicado: (2022)

Prognostic stratification based on m(5)C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Ping, et al.
Publicado: (2022)

The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma
por: Ding, Yixin, et al.
Publicado: (2023)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions
por: Wang, Mingming, et al.
Publicado: (2023)

Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
por: Li, Shuqun, et al.
Publicado: (2023)

Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy
por: Yin, Li, et al.
Publicado: (2022)

Current Status and Future Directions of Bacteria-Based Immunotherapy
por: Tang, Quan, et al.
Publicado: (2022)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
por: Wang, Kunpeng, et al.
Publicado: (2021)

Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population–based analysis
por: Zhao, Jingjing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pj0f2o1gn1oeg1rb8v1e0u8aep